Skip to main content
. Author manuscript; available in PMC: 2019 Oct 9.
Published in final edited form as: Regen Med. 2015;10(5):623–646. doi: 10.2217/rme.15.25

Table 2.

Clinical transplantation in Huntington’s disease.

Study (year) Clinical size Type of cell Clinical outcome Negative effects Ref.
Bachoud-Levi et al. (2006, 2009, 2000) Five patients Whole ganglionic eminence Three of five patients showed stability of symptoms or clinical improvement for 4–6 years One patient showed development of a putaminial cyst [4,99,108]
Capetian et al. (2009) One patient Whole ganglionic eminence UHDRS score stability for 6 months. Survival and differentiation of grafted cells None reported (patient died from unrelated causes) [109]
Cicchetti et al. (2009, 2014) Three patients Lateral ventricular eminence containing striatal primordia Improvement of UHDRS in two of three patients for up to 18 months before returning to presurgical levels Grafts underwent disease-like neuronal degeneration. Cortical hemorrhage, subdural hematoma following surgery [5,100]
Freeman et al. (2000) One patient Lateral ventricular eminence containing striatal primordia Stability of UHDRS 15 months following transplantation. Transplants integrated into the host tissue None reported [110]
Furtado et al. (2005) Seven patients Fetal striatal tissue Transplants failed to restore fluorodeoxyglucose uptake and D1 and D2 receptor binding in subjects Possible technical issues with regards to the ganglionic eminence and in targeting the striatum [111]
Hauser et al. (2002) Seven patients Fetal striata Grafts developed striatal morphology, UHDRS improved significantly 12 months following surgery Three subjects developed subdural hemorrhages, one patient died 18 months following surgery from probable cardiac arrhythmia [112]
Keene et al. (2007) Two patients Fetal lateral ganglionic eminence Improved ambulation 3 months following transplant in one patient. In both patients, transplanted cells displayed morphology of neurons and astrocytes One patient reported chronic headaches following surgery and was treated for bilateral subdural hematomas. Reported that transplants did not have an effect on the course of HD [113]
Keene et al. (2009) One patient Fetal neuronal tissue Clinical improvement for UHDRS for 2 years. Patient died 121 months following surgery from complications of advanced HD Three mass lesions and one large cyst were present on the left caudate and putamen. Five mass lesions and two cysts were present on the right caudate and putamen [6]
Kopyov et al. (1998) Three patients Lateral ganglionic eminence Clinical improvement for UHDRS for all three patients 12 months following surgery. Graft survival and growth within the striatum without displacing host tissue None reported [114]
Krystkowiak et al. (2007) 13 patients Fetal neuronal tissue Pre- and post-UHDRS were not reported. Four of the 13 patients had grafts that did not display signs of rejection Biological, radiological and clinical rejection of grafts in other subjects (reversible under immunosuppressive treatment) [115]
Reuter et al. (2008) Two Patients Whole ganglionic Eminence Clinical improvement for UHDRS over 5-year period for one patient. Increased striatal D2 receptor binding, suggesting long-term survival and efficacy of grafts None reported [101]
Rosser et al. (2002) Four Patients Whole ganglionic Eminence Stability of UHDRS as well as cognitive ability up to 6 months following surgery. Graft survival without Overgrowth None reported [116]
Philpott et al(1997) Three Patients Lateral ganglionic Eminence Increased cognitive functioning 6 months following surgery None reported [117]
Gallina et al. (2010) Four Patients Whole ganglionic Eminence Stability or improvement in motor, behavioral and functional scores up to 24 months following surgery None reported [104]
Madrazo et al. (1995) Two patients Whole ganglionic eminence Stability or improvement on functional capacity for up to 25 months following surgery when a slow progression of HD was observed None reported [118]

HD: Huntingdon’s disease; UHDRS: Unified Huntingdon’s disease rating scale.

HHS Vulnerability Disclosure